Clinical Trial Update: Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating complement component 3c and TNF-α in HPV-induced cutaneous warts has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warts

Snippet

Sponsor: Zagazig University | Conditions: Warts | Phase 2 | Status: COMPLETED